🇺🇸 FDA
Pipeline program

Subutex 300 mg injektionsvätska, depotlösning, Subutex 100 mg injektionsvätska, depotlösning

INDV-6000-406

Approved small_molecule active

Quick answer

Subutex 300 mg injektionsvätska, depotlösning, Subutex 100 mg injektionsvätska, depotlösning for Opioid Use Disorder is a Approved program (small_molecule) at Indivior Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Indivior Europe Limited
Indication
Opioid Use Disorder
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials